*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
The global pharmaceutical business has gone through noticeable changes during the past couple of years, with China in particular having evolved in significant ways, according to a new PricewaterhouseCoopers' (PWC) report titled "Investing in China's Pharmaceutical Industry, Second Edition." The study looks into the current conditions of the pharmaceutical market in China.
During this week's podcast, PWC's Michael Keech describes how the pharmaceutical/life sciences arena in China has changed since publication of the first edition of the report. He talks about the main strengths of the Chinese pharma industry and discusses the key drivers for the ongoing growth of that country's pharmaceutical industry.
Keech also lists the Chinese market opportunities that present themselves to non-Chinese life science firms and explains how traditional Chinese medicine fits into the country's pharmaceutical efforts. In addition, he reviews what the Chinese government has done recently to tackle issues such as intellectual property protection as well as bribery and corruption in the sales and marketing segments of the Chinese pharmaceutical industry, long bugaboos for companies doing business in China.
Director, Pharmaceutical & Life Sciences
Advisory Services Group
Michael Keech is a director and co-leader of the U.S. Pharmaceutical and Life Sciences Supply Chain Services Practice for PricewaterhouseCoopers (PwC). Michael has over 12 years of experience working with many of the leading pharmaceutical & biotechnology companies. His area of expertise is in assisting firms with achieving transformational change through operations improvement in supply chain strategy and manufacturing operations.
Prior to joining PwC, he held supply chain and manufacturing leadership positions for two respected pharmaceutical companies. As a senior director at OSI Pharmaceuticals, Michael managed the complete supply chain in this start-up biotechnology organization, including strategic sourcing, manufacturing and packaging operations, distribution logistics and transportation. In addition to OSI, Michael worked at Wyeth and led the company's global supply chain strategy across the company’s pharmaceutical, vaccines and consumer business units.
Prior to his industry experience, he worked as a consultant with two leading international consulting firms where he focused on global supply chain strategy in the pharmaceutical and biotech industry. Michael received a BS in Logistics from the Pennsylvania State University and a MBA from the University of Tennessee.